• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia.

作者信息

Maiti Abhishek, DiNardo Courtney D, Daver Naval G, Rausch Caitlin R, Ravandi Farhad, Kadia Tapan M, Pemmaraju Naveen, Borthakur Gautam, Bose Prithviraj, Issa Ghayas C, Short Nicholas J, Yilmaz Musa, Montalban-Bravo Guillermo, Ferrajoli Alessandra, Jabbour Elias J, Jain Nitin, Ohanian Maro, Takahashi Koichi, Thompson Philip A, Loghavi Sanam, Montalbano Kathryn S, Pierce Sherry, Wierda William G, Kantarjian Hagop M, Konopleva Marina Y

机构信息

Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Division of Pharmacy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

出版信息

Blood Cancer J. 2021 Feb 1;11(2):25. doi: 10.1038/s41408-021-00410-w.

DOI:10.1038/s41408-021-00410-w
PMID:33563904
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7873265/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2de1/7873265/85ef55c34acb/41408_2021_410_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2de1/7873265/85ef55c34acb/41408_2021_410_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2de1/7873265/85ef55c34acb/41408_2021_410_Fig1_HTML.jpg

相似文献

1
Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia.维奈克拉、FLT3抑制剂和地西他滨三联疗法治疗FLT3突变的急性髓系白血病。
Blood Cancer J. 2021 Feb 1;11(2):25. doi: 10.1038/s41408-021-00410-w.
2
Menin inhibition decreases Bcl-2 and synergizes with venetoclax in NPM1/FLT3-mutated AML.Menin抑制作用可降低Bcl-2水平，并在NPM1/FLT3突变的急性髓系白血病中与维奈托克协同作用。
Blood. 2021 Oct 28;138(17):1637-1641. doi: 10.1182/blood.2021011917.
3
[The clinical safety and efficacy of the patients of acute myeloid leukemia with FLT3-ITD positive treated with sorafenib in combination with venetoclax and azactitidine regimen].[索拉非尼联合维奈克拉及阿扎胞苷方案治疗FLT3-ITD阳性急性髓系白血病患者的临床安全性和疗效]
Zhonghua Xue Ye Xue Za Zhi. 2022 Nov 14;43(11):956-959. doi: 10.3760/cma.j.issn.0253-2727.2022.11.013.
4
Targeted therapies in Acute Myeloid Leukemia: a focus on FLT-3 inhibitors and ABT199.急性髓系白血病的靶向治疗：聚焦于FLT-3抑制剂和ABT199。
Expert Rev Hematol. 2017 Oct;10(10):863-874. doi: 10.1080/17474086.2017.1366852. Epub 2017 Aug 21.
5
Triplet therapy with gilteritinib, venetoclax, and azacitidine for relapsed/refractory FLT3 acute myeloid leukemia.吉特替尼、维奈托克和阿扎胞苷三联疗法治疗复发/难治性 FLT3 急性髓系白血病。
Leuk Res. 2024 Oct;145:107564. doi: 10.1016/j.leukres.2024.107564. Epub 2024 Aug 22.
6
Rationale for Combining the BCL2 Inhibitor Venetoclax with the PI3K Inhibitor Bimiralisib in the Treatment of IDH2- and FLT3-Mutated Acute Myeloid Leukemia.将 BCL2 抑制剂 Venetoclax 与 PI3K 抑制剂 Bimiralisib 联合用于治疗 IDH2 和 FLT3 突变的急性髓系白血病的理由。
Int J Mol Sci. 2022 Oct 20;23(20):12587. doi: 10.3390/ijms232012587.
7
Molecular responses in decitabine- and decitabine/ venetoclax-treated patients with acute myeloid leukemia and myelodysplastic syndromes.地西他滨和地西他滨/维奈克拉治疗的急性髓系白血病和骨髓增生异常综合征患者的分子反应
Haematologica. 2024 Aug 1;109(8):2653-2659. doi: 10.3324/haematol.2022.281396.
8
Alternating venetoclax/azacytidine and FLT3 inhibitor treatment for NPM1- and FLT3-mutated acute myeloid leukemia.维奈克拉/阿扎胞苷交替联合FLT3抑制剂治疗NPM1和FLT3突变的急性髓系白血病
Leuk Res. 2023 Jul;130:107313. doi: 10.1016/j.leukres.2023.107313. Epub 2023 May 16.
9
Synergistic effect of BCL2 and FLT3 co-inhibition in acute myeloid leukemia.BCL2 和 FLT3 共抑制在急性髓系白血病中的协同效应。
J Hematol Oncol. 2020 Oct 19;13(1):139. doi: 10.1186/s13045-020-00973-4.
10
Preclinical activity and a pilot phase I study of pacritinib, an oral JAK2/FLT3 inhibitor, and chemotherapy in FLT3-ITD-positive AML.在伴有 FLT3-ITD 突变的 AML 患者中，口服 JAK2/FLT3 抑制剂 pacritinib 联合化疗的临床前活性和 I 期临床试验研究。
Invest New Drugs. 2020 Apr;38(2):340-349. doi: 10.1007/s10637-019-00786-4. Epub 2019 May 17.

引用本文的文献

1
Unraveling Venetoclax Resistance: Navigating the Future of HMA/Venetoclax-Refractory AML in the Molecular Era.解析维奈托克耐药性：在分子时代探索HMA/维奈托克难治性急性髓系白血病的未来。
Cancers (Basel). 2025 May 7;17(9):1586. doi: 10.3390/cancers17091586.
2
Acute Myeloid Leukemia: 2025 Update on Diagnosis, Risk-Stratification, and Management.急性髓系白血病：2025年诊断、风险分层及管理的最新进展
Am J Hematol. 2025 May;100(5):860-891. doi: 10.1002/ajh.27625. Epub 2025 Feb 12.
3
Outcomes in patients with acute myeloid leukemia older than 70 years within the last 30 years, a single center experience.

本文引用的文献

1
10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial.10天阿扎胞苷联合维奈克拉用于新诊断的不适合强化化疗以及复发或难治性急性髓系白血病的治疗：一项单中心2期试验
Lancet Haematol. 2020 Oct;7(10):e724-e736. doi: 10.1016/S2352-3026(20)30210-6. Epub 2020 Sep 5.
2
Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia.阿扎胞苷和维奈托克治疗未经治急性髓系白血病。
N Engl J Med. 2020 Aug 13;383(7):617-629. doi: 10.1056/NEJMoa2012971.
3
Venetoclax combines synergistically with FLT3 inhibition to effectively target leukemic cells in FLT3-ITD+ acute myeloid leukemia models.
过去30年里70岁以上急性髓系白血病患者的治疗结果：单中心经验
Ann Hematol. 2025 Jan;104(1):231-239. doi: 10.1007/s00277-025-06196-2. Epub 2025 Jan 11.
4
[Efficacy and safety of gilteritinib combined with chemotherapy in newly diagnosed FLT3-mutated acute myeloid leukemia].吉瑞替尼联合化疗治疗新诊断的FLT3突变型急性髓系白血病的疗效与安全性
Zhonghua Xue Ye Xue Za Zhi. 2024 Dec 14;45(12):1129-1133. doi: 10.3760/cma.j.cn121090-20240615-00224.
5
Pre-emptive therapeutic decisions based on measurable residual disease status in acute myeloid leukemia: ready for prime time?基于急性髓系白血病可测量残留病状态的抢先治疗决策：准备好进入黄金时代了吗？
Leukemia. 2025 Jan;39(1):1-7. doi: 10.1038/s41375-024-02458-6. Epub 2024 Nov 5.
6
The prognostic significance of genetics in acute myeloid leukemia under venetoclax-based treatment.在基于维奈克拉的治疗方案下，遗传学在急性髓系白血病中的预后意义。
Ann Hematol. 2024 Dec;103(12):5019-5033. doi: 10.1007/s00277-024-06050-x. Epub 2024 Oct 29.
7
Azacitidine in combination with shortened venetoclax treatment cycles in patients with acute myeloid leukemia.阿扎胞苷联合缩短维奈克拉治疗周期用于急性髓系白血病患者
Ann Hematol. 2025 Jan;104(1):285-294. doi: 10.1007/s00277-024-06048-5. Epub 2024 Oct 25.
8
Venetoclax triggers sublethal apoptotic signaling in venetoclax-resistant acute myeloid leukemia cells and induces vulnerability to PARP inhibition and azacitidine.维奈托克在维奈托克耐药的急性髓系白血病细胞中触发亚致死性凋亡信号，并诱导对 PARP 抑制和阿扎胞苷的易感性。
Cell Death Dis. 2024 Oct 16;15(10):750. doi: 10.1038/s41419-024-07140-4.
9
Intensive induction chemotherapy vs hypomethylating agents in combination with venetoclax in NPM1-mutant AML.NPM1 突变型 AML 中强化诱导化疗与低甲基化药物联合维奈托克的比较。
Blood Adv. 2024 Sep 24;8(18):4845-4855. doi: 10.1182/bloodadvances.2024012858.
10
Combination therapy with novel agents for acute myeloid leukaemia: Insights into treatment of a heterogenous disease.新型药物联合治疗急性髓系白血病：异质性疾病治疗的新视角。
Br J Haematol. 2024 Jul;205(1):30-47. doi: 10.1111/bjh.19519. Epub 2024 May 9.
维奈托克与 FLT3 抑制联合具有协同作用，可有效靶向 FLT3-ITD+ 急性髓系白血病模型中的白血病细胞。
Haematologica. 2021 Apr 1;106(4):1034-1046. doi: 10.3324/haematol.2019.244020.
4
Advances in the Treatment of Acute Myeloid Leukemia: New Drugs and New Challenges.急性髓系白血病治疗进展：新药与新挑战。
Cancer Discov. 2020 Apr;10(4):506-525. doi: 10.1158/2159-8290.CD-19-1011. Epub 2020 Feb 3.
5
Gilteritinib or Chemotherapy for Relapsed or Refractory -Mutated AML.吉特替尼与化疗用于治疗复发/难治性 - 突变型 AML。
N Engl J Med. 2019 Oct 31;381(18):1728-1740. doi: 10.1056/NEJMoa1902688.
6
Inhibition of Bcl-2 Synergistically Enhances the Antileukemic Activity of Midostaurin and Gilteritinib in Preclinical Models of FLT3-Mutated Acute Myeloid Leukemia.在 FLT3 突变的急性髓系白血病的临床前模型中，Bcl-2 的抑制作用与米哚妥林和吉特替尼协同增强抗白血病活性。
Clin Cancer Res. 2019 Nov 15;25(22):6815-6826. doi: 10.1158/1078-0432.CCR-19-0832. Epub 2019 Jul 18.
7
Incorporating FLT3 inhibitors in the frontline treatment of FLT3 mutant acute myeloid leukemia.将 FLT3 抑制剂纳入 FLT3 突变型急性髓系白血病的一线治疗。
Best Pract Res Clin Haematol. 2019 Jun;32(2):154-162. doi: 10.1016/j.beha.2019.05.006. Epub 2019 May 12.
8
Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial.Quizartinib 与挽救性化疗治疗复发或难治性 FLT3-ITD 急性髓系白血病（QuANTUM-R）：一项多中心、随机、对照、开放标签、3 期临床试验。
Lancet Oncol. 2019 Jul;20(7):984-997. doi: 10.1016/S1470-2045(19)30150-0. Epub 2019 Jun 4.
9
Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia.维奈托克联合地西他滨或阿扎胞苷治疗初治老年急性髓系白血病患者。
Blood. 2019 Jan 3;133(1):7-17. doi: 10.1182/blood-2018-08-868752. Epub 2018 Oct 25.
10
Sorafenib Combined with 5-azacytidine in Older Patients with Untreated FLT3-ITD Mutated Acute Myeloid Leukemia.索拉非尼联合 5-氮杂胞苷治疗未经治疗的 FLT3-ITD 突变的老年急性髓系白血病患者。
Am J Hematol. 2018 Sep;93(9):1136-1141. doi: 10.1002/ajh.25198. Epub 2018 Aug 31.